HSCT has also been performed in sporadic cases of patients with MECOM-associated syndrome presenting and bone marrow failure [15], thrombocytopenia with radioulnar synostosis (RUSAT1), thrombocytopenia with absent radii (TAR), BSS, GT, GPS, and CHS, and could be appropriate in patients with FPD/AML or ANKRD26-RT or ETV6-RT who develop hematological neoplasms [5,18,22,106,166]. This evidence concerns the gene ETV6 and acute myeloid leukemia.